AI Analysis AI Analysis of MRUS
AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment
Trading Strategy
PDF

Red day on Monday for Merus NV
(Updated on Nov 17, 2025)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Buy or Hold candidate since Jul 09, 2025 Gain 75.89%

The Merus NV stock price fell by -0.0730% on the last day (Monday, 17th Nov 2025) from $95.95 to $95.88. During the last trading day the stock fluctuated 0.544% from a day low at $95.65 to a day high of $96.17. The price has risen in 7 of the last 10 days and is up by 1.16% over the past 2 weeks. Volume has increased on the last day by 423 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $148.24 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 61.21% during the next 3 months and, with a 90% probability hold a price between $148.42 and $176.02 at the end of this 3-month period.

MRUS Signals & Forecast

The Merus NV stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $95.73 and $94.87. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, November 13, 2025, and so far it has fallen -0.208%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Merus NV stock

Merus NV finds support from accumulated volume at $94.88 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the stock tends to have very controlled movements and with good liquidity the risk is considered very low in this stock. During the last day, the stock moved $0.520 between high and low, or 0.544%. For the last week the stock has had daily average volatility of 0.504%.

Our recommended stop-loss: $93.37 (-2.61%) (This stock has very low daily movements and this gives very low risk. There is a sell signal from a pivot top found 2 days ago.)

Trading Expectations (MRUS) For The Upcoming Trading Day Of Tuesday 18th

For the upcoming trading day on Tuesday, 18th we expect Merus NV to open at $95.90, and during the day (based on 14 day Average True Range), to move between $95.55 and $96.21, which gives a possible trading interval of +/-$0.665 (+/-0.70%) up or down from last closing price. If Merus NV takes out the full calculated possible swing range there will be an estimated 0.70% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $95.95 (0.07%) than the support at $94.88 (1.04%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Merus NV stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Merus NV stock to perform well in the short-term.

Current score: 3.052 Buy Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on November 18, 2025 - $95.90 ( 0.0209%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk

MRUS Performance

Trading levels for MRUS

Full Access. No Commitment. 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 5 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 96.42 0.563%
R2 96.22 0.356%
R1 96.10 0.228%
Price 95.88
S1 95.70 -0.186%
S2 95.58 -0.314%
S3 95.38 -0.521%

Accumulated Volume Support & Resistance Levels

Level Price
R3 96.08 0.209%
R2 96.04 0.167%
R1 95.95 0.0730%
Price 95.88
S1 94.88 -1.04%
S2 94.15 -1.80%
S3 93.67 -2.30%

FAQ

What is the symbol for Merus NV Stock and on which exchange is it traded?
The symbol for Merus NV is MRUS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Merus NV Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Merus NV stock to perform well in the short-term.

How to buy Merus NV Stock?
Merus NV Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Merus NV Stock.

What's the current price of Merus NV Stock?
As of the end of day on the Nov 17, 2025, the price of an Merus NV (MRUS) share was $95.88.

What is the 52-week high and low for Merus NV Stock?
The 52-week high for Merus NV Stock is $96.30 and the 52-week low is $33.19.

What is the market capitalization of Merus NV Stock?
As of the Nov 17, 2025, the market capitalization of Merus NV is 7.272B.

When is the next earnings date for Merus NV?
The upcoming earnings date for Merus NV is Feb 26, 2026.
Click to get the best stock tips daily for free!
ABOUT MERUS NV
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE